FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

wasni	ngton,	D.C.	20549

Check this box if no longer subject to	ST
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average b	urden
haura nar raananaa.	٥٦

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Wolchko J Scott				2. Issuer Name and Ticker or Trading Symbol FATE THERAPEUTICS INC [FATE]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
WOICHKO J SCOU										-		X	Direc	ctor	10%	Owner			
(Last) (First) (Middle)			3. [Date of Earliest Transaction (Month/Day/Year)							$\overline{}$	X	Office below	er (give title v)	Other below	(specify y)			
C/O FAT	E THERAF	EUTICS, INC.;			10/	10/15/2019							President and CEO						
3535 GE	NERAL AT	OMICS COUR	Γ#20	0															
					- 4. II	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SAN DIE	EGO CA	1 (92121											X	-/				
				-	-									Form filed by More than One Reporting Person				porting	
(City)	(St	ate) (Zip)																
		Tabl	le I -	Non-Deriv	/ative	Sec	uritie	s A	cquir	ed, D	isposed o	f, or E	Benefici	ally (Owne	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y				Execution Date,		te,	3. Transaction Code (Instr. 8) 4. Securities Acquired (A) 0 Disposed Of (D) (Instr. 3, 4				nd 5) S		ount of ities icially d Following rted	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								v	Amount	(A) or (D)	Price		Trans	action(s) 3 and 4)		(our .)			
Common Stock		10/15/20	19				S		21,017(1)	D	\$14.43	87 ⁽²⁾	35	3,969(3)	D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Derivative Security (Instr. 3) Conversion or Exercise Price of Derivative Security Detail of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Execution Date, or Conversion or Exercise (Month/Day/Year)		4. Transa Code 8)	(Instr.	5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	rities ired r osed)	Expi (Mor	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Number of		-		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

Explanation of Responses:

- 1. Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 43,125 shares of Common Stock underlying restricted stock units ("RSUs") granted to the reporting person on October 15, 2015. This sale was made pursuant to an irrevocable election on December 22, 2018 by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- 2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$13.94 to \$14.695 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. All remaining shares of Common Stock held by the reporting person are subject to the terms of a lock-up agreement with Jefferies LLC and Citigroup Global Markets Inc. (the "Representatives"), as representatives of the underwriters in the Company's public offering pursuant to a prospectus supplement dated September 11, 2019, pursuant to which the reporting person agreed, without the prior written consent of the Representatives, and subject to limited exceptions, not to sell, offer to sell, contract to sell or lend, effect any short sale, pledge, hypothecate or grant any security interest in, or otherwise transfer or dispose of, any shares of Common Stock, either directly or indirectly.

Remarks:

/s/ Cindy R. Tahl, as Attorney-10/16/2019

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.